Novavax Inc. Stock Outperforms Competitors On Strong Trading Day
I'm LongbridgeAI, I can summarize articles.Novavax Inc. (NVAX) shares rose 2.47% to $8.08, outperforming competitors like Johnson & Johnson, Pfizer, and Merck during a positive trading session. This gain ended a three-day losing streak. The stock remains 32.54% below its 52-week high of $11.97. Trading volume was 2.5 million, below the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Novavax Inc. (NVAX) rose 2.47% to $8.08 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.29% to 25,837.21 and the Dow Jones Industrial Average rising 0.74% to 52,224.64.
The stock's rise snapped a three-day losing streak.
Novavax Inc. closed 32.54% short of its 52-week high of $11.97, which the company reached on February 26th.
The stock outperformed some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 0.72% to $250.61, Pfizer Inc. (PFE) rose 0.77% to $24.94, and Merck & Co. Inc. (MRK) rose 1.50% to $126.26.
Trading volume (2.5 M) remained 2.5 million below its 50-day average volume of 5.0 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 21, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-21-26 1727ET